- NASDAQ: SRNE is on course for a 10% above $20, on top of the 30% rally on Monday.
- Sorrento Therapeutics is benefiting after announcing buying a COVID-19 therapy developer.
- Demand for coronavirus immunization is on the rise despite Russia's vaccine breakthrough.
Serenity for Sorrento Therapeutics investors – NASDAQ: SRNE is set to extend its gains, proving it is more than a one-day wonder in equity markets. The California-based pharma firm's shares are on the rise following its move into the coronavirus space.
Sorrento announced it is planning to acquire SmartPharm Therapeutics, a company providing therapy for COVID-19. Managers also said it licensed the rights to a rapid test – identifying the virus in saliva within 30 minutes.
While some skeptics doubt Sorrento's fast and furious announcements, investors are piling up, pushing SRNE's valuation to around $4.5 billion at the time of writing.
Demand for any cure or vaccine for the novel coronavirus is at elevated levels. Companies that announce progress – whether in a clinical or earlier trial – see their shares rise quickly, especially from the Robinhood crowd.
Russian President Vladimir V. Putin declared that his country registered the world's first coronavirus vaccine – and that his daughter already received it. If immunization is already available, why would other efforts still make sense?
First, Putin's claims are met with doubts –scientists want to see the underlying data before hailing Moscow's Gamaleya Institute's achievement. This is not another Sputnik moment. Moreover, it is unclear how long any vaccine is effective – antibodies tend to disappear from recovered coronavirus patients.
And while those that have a large number of defenses against the SARS-Cov-2 virus may avoid illness, they could remain infectious and those who are unprotected could suffer. There is still a need for a coronavirus cure, not only a vaccine.
SRNE Stock Price
NASDAQ: SRNE soared by over 30% to close at $18.82 on Monday. Tuesday's pre-market trading is pointing to another leap of around 10% to above the $20 mark, putting Sorrento's share price above the 52-week high of $19.39.
It is essential to stress that SRNE changed hands as low as $1.39 in the past 52 weeks.
More: Novavax receives bullish $290 share target amid coronavirus vaccine progress
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD climbs to 10-day highs above 1.0700
EUR/USD gained traction and rose to its highest level in over a week above 1.0700 in the American session on Tuesday. The renewed US Dollar weakness following the disappointing PMI data helps the pair stretch higher.
GBP/USD extends recovery beyond 1.2400 on broad USD weakness
GBP/USD gathered bullish momentum and extended its daily rebound toward 1.2450 in the second half of the day. The US Dollar came under heavy selling pressure after weaker-than-forecast PMI data and fueled the pair's rally.
Gold rebounds to $2,320 as US yields turn south
Gold reversed its direction and rose to the $2,320 area, erasing a large portion of its daily losses in the process. The benchmark 10-year US Treasury bond yield stays in the red below 4.6% following the weak US PMI data and supports XAU/USD.
Here’s why Ondo price hit new ATH amid bearish market outlook Premium
Ondo price shows no signs of slowing down after setting up an all-time high (ATH) at $1.05 on March 31. This development is likely to be followed by a correction and ATH but not necessarily in that order.
Germany’s economic come back
Germany is the sick man of Europe no more. Thanks to its service sector, it now appears that it will exit recession, and the economic future could be bright. The PMI data for April surprised on the upside for Germany, led by the service sector.